Cytokinetics posts MAPLE-HCM presentation on aficamten vs metoprolol in obstructive hypertrophic cardiomyopathy

• Cytokinetics published a MAPLE-HCM analysis comparing aficamten versus metoprolol monotherapy in symptomatic obstructive hypertrophic cardiomyopathy.
• Document reiterates trial finding that aficamten outperformed metoprolol, with metoprolol showing no improvement in LVOT gradient.
• Substudy tests whether prior beta-blocker use biased results by analyzing outcomes in patients with pretrial beta-blocker exposure versus none.
• Participants received 24-week treatment with aficamten 5-20 mg daily or metoprolol 50-200 mg daily, with dose titration.
• Pretrial groups included beta-blocker naive patients (52) versus beta-blocker users (123); a smaller SOC-naive subset totaled 22.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief on August 29, 2026, and is solely responsible for the information contained therein.